Views: 0 Author: Site Editor Publish Time: 2026-11-16 Origin: Site
HKeyBio Industry Commentary
BAFF and APRIL in B Cell Survival and Autoimmune Drug Development
Autoimmune Disease Targets and Models Series 30
Originally published in Chinese on June 17, 2025. Drug approvals and development stages are presented as of that date.
HKeyBio’s take. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) help sustain different stages of the B-cell lineage. Their overlapping roles explain why drug developers have pursued both selective BAFF inhibition and dual BAFF/APRIL blockade. The choice of disease model depends on which cells and effects a program needs to study.
01 How BAFF and APRIL support B cells and plasma cells
02 The global development landscape for BAFF/APRIL therapies
03 The rationale for targeting BAFF/APRIL across indications
04 Animal models for BAFF/APRIL-related indications
A bibliometric study published online in Cellular Signalling in May 2024 mapped BAFF/APRIL research from 1999 to 2023. It traced 25 years of discoveries and identified major research themes and emerging directions [1].
BAFF, also known as BLyS or TNFSF13B, and APRIL, also known as TNFSF13A, are members of the tumor necrosis factor (TNF) superfamily. APRIL was reported in 1998 and was first linked to proliferation in certain tumor-cell systems. BAFF was described in 1999 and was found to support B-lymphocyte growth [7,8].
The expression of both ligands varies by cell type, activation state and disease. Myeloid cells, including dendritic cells, monocytes, neutrophils and macrophages, are important sources. Outside the immune compartment, expression has been reported in settings such as astrocytes in multiple sclerosis lesions, tonsillar and salivary gland epithelium, osteoclasts in rheumatoid arthritis, mammary adipocytes and renal cells including mesangial cells and podocytes in studies of IgA nephropathy. Which ligand is expressed and how much it contributes depend on the tissue and disease context [2,4,6].
Both ligands support cells of the B-cell lineage at different stages. BAFF signals through BAFF receptor (BAFF-R) to help transitional B cells that have passed bone-marrow selection survive and mature into functional naïve B cells. Loss of this survival signal results in a marked depletion of mature peripheral B cells [4,6].
APRIL acts at later stages by supporting immunoglobulin class switching and the survival of antibody-secreting cells, including differentiated CD20-negative plasmablasts and plasma cells. It contributes to IgA production. Studies in IgA nephropathy (IgAN) have reported elevated APRIL or BAFF in different cohorts. APRIL has been associated with proteinuria in some studies and increased before post-transplant recurrence in one cohort. These observations support further study of APRIL as a biomarker [2,9].
In Lafayette and colleagues’ randomized IgAN trial, rituximab depleted circulating B cells but did not significantly improve proteinuria or kidney function over one year. The persistence of antibody-producing cells that lack CD20 is one possible explanation. The trial did not directly test that mechanism [3].
Figure 1. B-cell maturation, class switching and antibody-secreting cell survival. Source: Bossen and Schneider [4].
Three principal receptors mediate BAFF and APRIL signaling [4–6].
BAFF-R. Also known as BR3 or TNFRSF13C, BAFF-R binds BAFF and supports peripheral B-cell survival and maturation, especially the transition from the T2 stage to mature B cells. Loss-of-function mouse studies show marked depletion of mature B cells.
TACI. Also known as TNFRSF13B, TACI binds both BAFF and APRIL. In marginal-zone and activated B cells, it can promote class switching to IgA or IgG, including in cooperation with Toll-like receptor 9 signaling. TACI can also restrain B-cell activation, and its deficiency can lead to lymphoproliferation.
BCMA. B-cell maturation antigen (TNFRSF17) binds APRIL preferentially and is expressed on plasmablasts and plasma cells. Studies cited in the original article link BCMA signaling to long-lived plasma-cell maintenance and sustained antibody production. The contribution of this pathway can vary by model and cell population.
Figure 2. BAFF/APRIL ligand forms and receptor interactions. Source: Vincent et al., Figure 1 [6].
Dysregulated BAFF/APRIL signaling can support autoreactive B-cell survival and pathological antibody responses. The pathway has been investigated in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS), IgAN, multiple sclerosis (MS) and myasthenia gravis (MG). The clinical rationale and evidence differ by indication.
Two approved agents illustrate the development landscape at the original publication date, June 17, 2025.
Belimumab. This monoclonal antibody binds soluble BAFF and prevents it from engaging BAFF-R, TACI and BCMA. In the United States, belimumab was FDA-approved for active SLE and active lupus nephritis in the indicated populations receiving standard therapy. Other biologics also had FDA approval for SLE, including anifrolumab [10,11].
Telitacicept. RemeGen’s TACI–Fc fusion protein combines the extracellular domain of human TACI with a human IgG Fc region. It acts as a decoy for both BAFF and APRIL. China had approved telitacicept for SLE, RA and adult anti-acetylcholine receptor antibody-positive generalized MG with conventional therapy by June 2025. Dual ligand blockade covers a broader set of ligand-dependent signals. Comparative clinical effects depend on the drug, dose and indication [12,13].
Investigational agents. Like telitacicept, atacicept is a TACI–Fc fusion protein that binds both ligands. Povetacicept is an engineered TACI–Fc variant designed for greater potency and more sustained pathway inhibition. Preclinical and early clinical pharmacology supported further study of that design [14].
Figure 3. Historical BAFF/APRIL development landscape. Source: New Drug Intelligence Database. Historical snapshot of June 17, 2025.
In autoimmune disease, B cells and plasma cells can produce antibodies to self-antigens such as DNA, ribosomal components and other proteins. B cells also influence disease through antigen presentation and cytokine production. Reducing survival signals to autoreactive B-cell populations could reduce pathogenic antibody production and immune-mediated injury where those populations drive disease. The potential benefit depends on which B-cell or plasma-cell populations sustain the disease and which are affected by the intervention.
In MS, antibody-independent B-cell functions are especially relevant. In the phase 2 ATAMS trial, atacicept increased relapse activity, prompting early termination [15]. This clinical result distinguishes BAFF/APRIL blockade from other B-cell-directed approaches in MS.
Figure 4. B-cell and plasma-cell functions in SLE, rheumatoid arthritis and multiple sclerosis.
HKeyBio develops models across species, strains, mechanisms and disease subtypes. The portfolio gives drug developers a choice of models aligned with the target, disease features and questions they need to answer. The table summarizes examples from the company’s June 2025 portfolio.
Table 1. HKeyBio animal models relevant to the indications discussed. Source: HKeyBio historical model matrix. Confirm the strain and protocol for each model when planning a study.
The following figures show representative HKeyBio model data. Treatment identity, sample sizes and full statistical methods were not provided in the original article.
Toll-like receptor 7 is an innate sensor of single-stranded RNA. It can also respond to self-RNA in appropriate contexts. Excess TLR7 signaling can promote autoreactive B- and T-cell responses and lupus-like disease, including autoantibodies associated with RNA-containing self-antigens. HKeyBio illustrates this approach in cynomolgus macaques and C57BL/6 mice [16,17].
Figure 5. TLR7 agonist-induced cynomolgus SLE model.
Figure 6. TLR7 agonist-induced C57BL/6 SLE model.
Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) models features such as inflammation, demyelination, axonal loss and gliosis. B cells can contribute through antigen presentation and inflammatory cytokines. HKeyBio developed an EAE model using an antigen that includes B-cell epitopes. In B-cell-dependent MOG models, autoreactive B cells can present antigen to cognate T cells and promote disease. This dependence varies with the form of myelin oligodendrocyte glycoprotein (MOG) used [18].
Figure 7. MOG-induced EAE in C57BL/6 mice.
Type II collagen is a major cartilage protein. Collagen-induced arthritis (CIA) reproduces selected features of rheumatoid arthritis, including synovial hyperplasia, mononuclear-cell infiltration and cartilage damage. Researchers use CIA to study disease mechanisms and evaluate candidate therapies.
Figure 8. Collagen-induced arthritis in cynomolgus macaques.
Acetylcholine receptors (AChRs) mediate signaling at the neuromuscular junction. In AChR antibody-positive MG, autoantibodies reduce effective neuromuscular transmission and contribute to muscle weakness and fatigability. The illustrated mouse model uses footpad immunization with an AChR-derived peptide and measures anti-AChR antibody responses and muscle weakness.
Figure 9. AChR peptide (R97–116)-induced experimental autoimmune myasthenia gravis.
Bovine serum albumin (BSA) can form aggregates under certain conditions. In a classic experimental system, immune complexes containing hapten-conjugated BSA and polymeric IgA deposited in the glomerular mesangium. Polymeric IgA supported complex formation in that system. Reported findings included proteinuria, hematuria and glomerulonephritis [19]. The HKeyBio BSA model illustrates selected features of IgAN-like injury, including glomerular IgA staining and renal pathology.
Figure 10. HKeyBio BSA-associated IgAN-like model in C57BL/6 mice.
Salivary gland protein immunization can induce Sjögren’s-like disease in C57BL/6 mice. Reported findings include glandular apoptosis and greater expression of the M3 muscarinic receptor, together with inflammatory infiltration and reduced saliva secretion. Increased T helper 17 (Th17) responses have also been observed in cervical lymph nodes and salivary glands [20].
Figure 11. Salivary gland protein-induced Sjögren’s-like disease in C57BL/6 mice.
HKeyBio offers custom models and welcomes discussion of study requirements and research collaborations in autoimmune drug development.
HKeyBio is a preclinical contract research organization specializing in in vivo efficacy studies for autoimmune disease. Its core technical team has more than 20 years of experience in autoimmune drug development. It operates molecular, cellular, pathology, small-animal and analytical facilities in Suzhou Industrial Park, alongside nonhuman primate (NHP) study facilities in Suzhou and Guangxi. As reported in June 2025, the company had about 60 employees and project leads with master’s or doctoral degrees. Its team supports preclinical development and investigational new drug (IND) submissions.
· 20+ NHP models of autoimmune disease
· 200+ animal models of autoimmune disease
· Experience supporting 300+ autoimmune disease IND submissions
Disclaimer. This article is provided for general information and offers no investment advice. Readers are responsible for their decisions. HKeyBio makes no express or implied warranty as to the accuracy, reliability or completeness of the material. Please contact HKeyBio about any rights concerns so the material can be reviewed and removed where appropriate.
[1] Balasubramaniam M, Mokhtar AMA. Past and present discovery of the BAFF/APRIL system. Cell Signal. 2024;120:111201. Source
[2] Suzuki Y. B cell targeting in IgA nephropathy. Nephrology (Carlton). 2024;29(Suppl 2):39–43. Source
[3] Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306–1313. Source
[4] Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol. 2006;18:263–275. Source
[5] KK’s Learning Castle (WeChat). Tracing the BAFF/APRIL system through telitacicept. Chinese-language source cited in the original article.
[6] Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24:203–215. Source
[7] Hahne M, Kataoka T, Schröter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188:1185–1190. Source
[8] Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747–1756. Source
[9] A proliferation-inducing ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: A review of the evidence. 2023. Source
[10] US Food and Drug Administration. Benlysta (belimumab) prescribing information. Revised May 2024. Source
[11] US Food and Drug Administration. Saphnelo (anifrolumab-fnia) approval package. July 30, 2021. Source
[12] RemeGen Co., Ltd. 2024 Interim Report. Telitacicept product pipeline and approvals in China. Source
[13] RemeGen Co., Ltd. Telitacicept for the treatment of generalized myasthenia gravis approved in China. May 27, 2025. Source
[14] A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept in healthy adults. Source
[15] Kappos L, Hartung HP, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS). Lancet Neurol. 2014;13:353–363. Source
[16] Brown GJ, Cañete PF, Wang H, et al. TLR7 gain-of-function genetic variation causes human lupus. Nature. 2022;605:349–356. Source
[17] Yokogawa M, Takaishi M, Nakajima K, et al. Epicutaneous application of Toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice. Arthritis Rheumatol. 2014;66:694–706. Source
[18] Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013;210:2921–2937. Source
[19] History of IgA nephropathy mouse models. 2021. Source
[20] Lin X, Rui K, Deng J, et al. Th17 cells play a critical role in the development of experimental Sjögren’s syndrome. Ann Rheum Dis. 2015;74:1302–1310. Source